Breast Cancer Clinical Trial

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

Summary

The reason for this study is to see if the CD73 inhibitor LY3475070 alone or in combination with pembrolizumab is safe and effective in participants with advanced cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants must have certain types of cancer such as breast cancer, pancreatic cancer, lung cancer, kidney cancer, skin cancer (melanoma), prostate cancer, and ovarian cancer
Participants must have stopped other forms of treatment for the cancer
In the expansion cohorts participants must be able and willing to provide a sample of the tumor before beginning treatment and a sample during the treatment. For certain tumor types, the result of a test on the tumor sample may exclude the participant from the study
Participants must not be pregnant, and must agree to use birth control
Participants must have progressed through or be intolerant to therapies with known clinical benefit

Exclusion Criteria:

Participants must not have a current untreated tuberculosis, lung disease, heart disease, uncontrolled HIV, autoimmune disease, active hepatitis B or C virus infection or using corticosteroids
Participant must not have cancer that has spread to the brain
Participant must not have received a vaccine within the last 30 days
Participant must not have had bowel obstruction within the last 6 months, or intestinal surgery
Participant must not have an infection that is currently being treated

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

52

Study ID:

NCT04148937

Recruitment Status:

Completed

Sponsor:

Eli Lilly and Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 12 Locations for this study

See Locations Near You

Sarah Cannon Research Institute at HealthOne
Denver Colorado, 80218, United States
Florida Cancer Specialists ORLANDO/DDU
Lake Mary Florida, 32746, United States
START Midwest
Grand Rapids Michigan, 49546, United States
Washington University Medical School
Saint Louis Missouri, 63110, United States
Cleveland Clinic Foundation
Cleveland Ohio, 44195, United States
Sarah Cannon Research Institute SCRI
Nashville Tennessee, 37203, United States
University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
Peter MacCallum Cancer Centre
Melbourne Victoria, 3000, Australia
Addenbrookes Hospital
Cambridge Cambridgeshire, CB2 0, United Kingdom
Beatson West of Scotland Cancer Center
Glasgow Scotland, G12 0, United Kingdom
Christie NHS Foundation Trust
Manchester , M20 4, United Kingdom
Royal Marsden NHS Trust
Sutton , SM2 5, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

52

Study ID:

NCT04148937

Recruitment Status:

Completed

Sponsor:


Eli Lilly and Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.